US Pharmaceutical Contract Development Manufacturing Organization Market

ID: MRFR/Pharma/20199-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026
United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report: Size, Share, Trend Analysis By Service (Pharmaceutical Manufacturing Services, Drug Development Services and Biologics Manufacturing Services), By End Users (Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma and Other End Users) - Growth Outlook & Industry Forecast 2025 To 2035
US Pharmaceutical Contract Development Manufacturing Organization Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.18%
2024 Market Size$ 32.84 Billion
2025 Market Size$ 34.36 Billion
2035 Market Size$ 51.54 Billion
Key Players
Lonza Group
Catalent
Thermo Fisher Scientific
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
Recipharm
Trends
  • Increased Demand for Specialized Manufacturing
  • Focus on Regulatory Compliance and Quality Assurance
  • Adaptation to Biologics and Personalized Medicine
Opportunities
  • Rising Demand for Generic Drugs
  • Increased Focus on Supply Chain Resilience
  • Technological Advancements in Manufacturing Processes
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Active Pharmaceutical Ingredient
      2. 4.1.2 Formulation Development
      3. 4.1.3 Packaging Services
      4. 4.1.4 Quality Control
      5. 4.1.5 Regulatory Compliance
    2. 4.2 Healthcare, BY End Use (USD Billion)
      1. 4.2.1 Pharmaceutical Companies
      2. 4.2.2 Biotechnology Firms
      3. 4.2.3 Research Institutions
      4. 4.2.4 Contract Research Organizations
    3. 4.3 Healthcare, BY Service Type (USD Billion)
      1. 4.3.1 Manufacturing Services
      2. 4.3.2 Development Services
      3. 4.3.3 Packaging Services
      4. 4.3.4 Testing Services
    4. 4.4 Healthcare, BY Product Type (USD Billion)
      1. 4.4.1 Small Molecules
      2. 4.4.2 Biologics
      3. 4.4.3 Injectables
      4. 4.4.4 Oral Solid Dosage Forms
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Lonza Group (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Catalent (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Thermo Fisher Scientific (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Boehringer Ingelheim (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Fujifilm Diosynth Biotechnologies (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Recipharm (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Aenova Group (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Siegfried (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Alcami Corporation (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY END USE
    4. 6.4 US MARKET ANALYSIS BY SERVICE TYPE
    5. 6.5 US MARKET ANALYSIS BY PRODUCT TYPE
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    14. 6.14 HEALTHCARE, BY END USE, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    16. 6.16 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
    18. 6.18 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
      2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
      3. 7.2.3 BY SERVICE TYPE, 2026-2035 (USD Billion)
      4. 7.2.4 BY PRODUCT TYPE, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pharmaceutical Contract Development Manufacturing Organization Market Segmentation

US Pharmaceutical Contract Development Manufacturing Organization Market By Application (USD Billion, 2026-2035)

  • Active US Pharmaceutical Contract Development Manufacturing Organization Market Ingredient
  • Formulation Development
  • Packaging US Pharmaceutical Contract Development Manufacturing Organization Markets
  • Quality Control
  • Regulatory Compliance

US Pharmaceutical Contract Development Manufacturing Organization Market By End Use (USD Billion, 2026-2035)

  • US Pharmaceutical Contract Development Manufacturing Organization Market Companies
  • Biotechnology Firms
  • Research Institutions
  • Contract Research Organizations

US Pharmaceutical Contract Development Manufacturing Organization Market By US Pharmaceutical Contract Development Manufacturing Organization Market Type (USD Billion, 2026-2035)

  • Manufacturing US Pharmaceutical Contract Development Manufacturing Organization Markets
  • Development US Pharmaceutical Contract Development Manufacturing Organization Markets
  • Packaging US Pharmaceutical Contract Development Manufacturing Organization Markets
  • Testing US Pharmaceutical Contract Development Manufacturing Organization Markets

US Pharmaceutical Contract Development Manufacturing Organization Market By Product Type (USD Billion, 2026-2035)

  • Small Molecules
  • Biologics
  • Injectables
  • Oral Solid Dosage Forms

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.